Lexicon Pharmaceuticals LXRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$26.09M+85.3% | -$50.34M+74.9% | -$68.58M+68.3% | -$120.62M+40.3% | -$177.3M+8.4% | ||
| $555K-1.9% | $621K+16.3% | $628K+12.9% | $603K+3.8% | $566K-3.4% | ||
| $12.55M+2.5% | $12.52M-7.3% | $11.22M-26.1% | $10.58M-35.0% | $12.24M-19.6% | ||
| $1.98M+14.5% | $1.7M-7.9% | $1.61M-22.1% | $1.61M-29.5% | $1.73M-14.7% | ||
| —— | —— | —— | -$437K— | $921K— | ||
| $75K+124% | $50K+133% | -$478K-259% | -$417K-201% | -$313K-161% | ||
| —— | —— | —— | —— | $2.22M— | ||
| —— | —— | —— | —— | -$3.69M— | ||
| $783K-58.8% | $1.74M+315% | $1.25M+163% | $352K+132% | $1.9M+171% | ||
| —— | —— | —— | —— | -$167.43M+9.7% | ||
| $180.83M-14.1% | $139.84M-57.5% | $143.49M-52.6% | $159.39M-52.1% | $210.49M-44.3% | ||
| $183M-47.3% | $252.86M-19.6% | $305.86M+6.8% | $323.41M+45.0% | $346.95M+68.7% | ||
| $2.18M— | $113.02M— | —— | —— | —— | ||
| $53M— | $48M— | $45M— | $45M— | —— | ||
| $69.99M+79,630% | $0— | $0— | $0— | -$88K— | ||
| —— | —— | —— | —— | —— | ||
| $26.55M— | $0— | —— | —— | —— | ||
| $40.83M— | -$48.5M— | —— | —— | —— | ||
| $4.2M— | -$3.33M— | $44.11M— | —— | —— | ||
| $6.84M-45.9% | $8.33M-35.5% | $9.77M-25.3% | $11.3M-14.8% | $12.63M+7.4% | ||
| $2.95M-68.1% | $3.71M-60.1% | $5.16M-45.2% | $7.13M— | $9.23M— | ||
| $1.98M+14.5% | $1.7M-7.9% | $1.61M-22.1% | $1.61M-29.5% | $1.73M-14.7% | ||
| -$766K+34.6% | -$757K+34.3% | -$1.21M-104% | -$1.19M— | -$1.17M— | ||
| —— | —— | —— | —— | -$3.69M— | ||
| $783K-58.8% | $1.74M+315% | $1.25M+163% | $352K+132% | $1.9M+171% | ||
| $183M-47.3% | $252.86M-19.6% | $305.86M+6.8% | $323.41M+45.0% | $346.95M+68.7% | ||
| $26.55M— | $0— | —— | —— | —— | ||
| $138K— | $73K— | —— | —— | —— | ||
| $53M— | $48M— | $45M— | $45M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Lexicon Pharmaceuticals generate?
- Lexicon Pharmaceuticals (LXRX) generated -$99.6M in operating cash flow over the trailing twelve months.
- Where does Lexicon Pharmaceuticals's cash flow data come from?
- Every line is extracted from Lexicon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
